Search | GSK

ViiV Healthcare launches phase III programme evaluating a two-drug regimen combining dolutegravir and lamivudine for HIV-1 treatment

Media

First published: 16 August 2016

HIV care is a long-term prospect for those living with the disease, requiring life-long adherence to treatment.

https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-launches-phase-iii-programme-evaluating-a-two-drug-regimen-combining-dolutegravir-and-lamivudine-for-hiv-1-treatment/

ViiV Healthcare announces phase II study results for first two drug, long-acting injectable regimen for HIV-1 treatment

Media

First published: 23 February 2016

32 week maintenance data presented at CROI showed comparable viral suppression rates between injectable regimen and three drug oral regimen

https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-phase-ii-study-results-for-first-two-drug-long-acting-injectable-regimen-for-hiv-1-treatment/

Shionogi-ViiV Healthcare announces positive initial data from phase III study of dolutegravir-based regimen vs Atripla in HIV

Media

First published: 11 July 2012

Shionogi-ViiV Healthcare LLC today announced that initial results have been received from the Phase III SINGLE (ING114467) study of the investigational integrase inhibitor dolutegravir in treatment...

https://www.gsk.com/en-gb/media/press-releases/shionogi-viiv-healthcare-announces-positive-initial-data-from-phase-iii-study-of-dolutegravir-based-regimen-vs-atripla-in-hiv/

GSK presents phase III results for eltrombopag in hepatitis C virus related thrombocytopenia

Media

First published: 07 November 2011

Full results from ENABLE 1 and initial data from ENABLE 2 presented at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases

https://www.gsk.com/en-gb/media/press-releases/gsk-presents-phase-iii-results-for-eltrombopag-in-hepatitis-c-virus-related-thrombocytopenia/

ViiV Healthcare gains CHMP positive opinion for Juluca (dolutegravir/rilpivirine) in Europe

Media

First published: 23 March 2018

ViiV Healthcare today announced that the European Committee for Medicinal Products for Human Use has issued a Positive Opinion recommending marketing authorisation for Juluca.

https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-gains-chmp-positive-opinion-for-juluca-dolutegravirrilpivirine-in-europe/

GSK presents promising phase 2a data for chronic hepatitis B treatment

Media

First published: 28 August 2020

Chronic hepatitis B is a major global health problem that occurs when the body’s immune system is unable to fight off the virus.

https://www.gsk.com/en-gb/media/press-releases/gsk-presents-promising-phase-2a-data-for-chronic-hepatitis-b-treatment/

ViiV Healthcare announces positive CHMP opinion for Rukobia (fostemsavir), a first-in-class attachment inhibitor for the treatment of adults with multidrug-resistant HIV with few treatment options available

Media

First published: 11 December 2020

Fostemsavir addresses a critical unmet need in HIV care for those with little to no treatment options left.

https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-positive-chmp-opinion-for-rukobia-fostemsavir/

ViiV Healthcare announces positive phase 3 results from the BRIGHTE study of fostemsavir in heavily treatment-experienced patients with HIV

Media

First published: 27 October 2017

ViiV Healthcare, today announced results from the phase III BRIGHTE study of fostemsavir in heavily treatment-experienced (HTE) patients with HIV-1 infection.

https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-positive-phase-3-results-from-the-brighte-study-of-fostemsavir-in-heavily-treatment-experienced-patients-with-hiv/

ViiV Healthcare announces positive phase 3 results from the BRIGHTE study of fostemsavir at 48 weeks in heavily treatment-experienced patients with HIV

Media

First published: 31 October 2018

BRIGHTE study highlights ViiV Healthcare’s commitment to developing innovative medicines for all people living with HIV, including those heavily-treated and failing on current antiretroviral regimens

https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-positive-phase-3-results-from-the-brighte-study-of-fostemsavir-at-48-weeks-in-heavily-treatment-experienced-patients-with-hiv/

ViiV Healthcare submits regulatory application to the European Medicines Agency for fostemsavir, an investigational, first-in-class attachment inhibitor for the treatment of HIV in adults with few treatment options available

Media

First published: 10 January 2020

ViiV Healthcare submits regulatory application to the European Medicines Agency for fostemsavir.

https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-submits-regulatory-application-to-the-european-medicines-agency-for-fostemsavir/